A Guide to the European Union’s New AML/CFT Framework
Discover the implications of the EU’s compliance requirements for firms doing business in Europe.
Download the full guide nowThe French financial market regulator, Autorité des marchés financiers (AMF), has released customer due diligence (CDD) guidance for investment firms to clarify anti-money laundering and counter-terrorist financing (AML/CFT) obligations. The guidelines were released on October 2, 2023.
“[This guidance] sets out the due diligence obligations with regard to clients and their beneficial owners,” explains the AMF, “taking account of the essential contributions of the 4th directive and 5th directive, and notably the reinforcement of the risk-based approach…Specific explanations are provided on the regimes for…outsourcing of AML-CFT obligations.”
The October 2 guidelines cover four key areas, beginning with key CDD definitions and obligations and ending with insights on fulfilling them through third parties. They apply to:
Firms’ highlighted responsibilities center on identity verification for clients and beneficial owners, the importance of understanding the business relationship, and retention of information. The AMF focuses on:
Under the Financial Security Act (2003), the AMF was created by merging three formerly independent bodies: Commission des Opérations de Bourse (COB), the Conseil des Marchés Financiers (CMF), and the Conseil de Discipline de la Gestion Financière (CDGF). The AMF exercises its authority under Article L. 561-36 of the French Monetary and Financial Code.
The regulator has three core goals:
To help ensure their current procedures are compliant and up-to-date, regulated firms are encouraged to study the AMF’s most recent guidance. They may also wish to consult background resources the guidance refers to, especially articles L. 561-4-1 and the Monetary and Financial Code.
Discover the implications of the EU’s compliance requirements for firms doing business in Europe.
Download the full guide nowOriginally published 06 October 2023, updated 08 February 2024
Disclaimer: This is for general information only. The information presented does not constitute legal advice. ComplyAdvantage accepts no responsibility for any information contained herein and disclaims and excludes any liability in respect of the contents or for action taken based on this information.
Copyright © 2024 IVXS UK Limited (trading as ComplyAdvantage).